Stock · NSE

BIOCON

430.40▼ 2.30 (-0.53%)

Last 2 days · 15m candles26/5/2026, 18:08:29

Open: 434.55High: 435.15Low: 430.40Prev: 432.70

Positive

Neutral

Negative

News mentioning BIOCON

Sentiment: +50%← All news

VERIFIEDMint Markets·5d★ ON YOUR LIST

AI summary· POSITIVE

·The Nifty Pharma index has risen by approximately 11% in the last month.
·The Nifty Pharma index has outperformed the Nifty 50, which saw a 3.6% decline in the same period.
·Year-to-date, the Nifty Pharma index has gained 9.4%, while the Nifty 50 has fallen by an equal margin.

VERIFIEDET Markets·13d★ ON YOUR LIST

AI summary· POSITIVE

·Nifty has seen a rally following a recent downtrend.
·Analysts suggest a buy-on-dips strategy for the Nifty.
·KEI Industries, Grasim Industries, and Biocon are highlighted as potential stock picks with up to 15% upside for May.

VERIFIEDET Markets·14d★ ON YOUR LIST

AI summary· NEUTRAL

·Five NSE F&O stocks saw significant increases in futures open interest on May 11.
·These stocks included Dalmia Bharat, Tata Consumer Products, Kaynes Technology India, Bharti Airtel, and Biocon.
·The rise in open interest indicates increased trader participation and fresh positioning.

VERIFIEDET Stocks·14d★ ON YOUR LIST

AI summary· NEUTRAL

·Five NSE F&O stocks saw significant increases in futures open interest on May 11.
·These stocks included Dalmia Bharat, Tata Consumer Products, Kaynes Technology India, Bharti Airtel, and Biocon.
·The rise in open interest indicates increased trader participation and new positioning.

VERIFIEDMint Companies·18d★ ON YOUR LIST

AI summary· POSITIVE

VERIFIEDET Finance·18d★ ON YOUR LIST

AI summary· NEUTRAL

·Biocon is prioritizing capacity utilization and margin expansion after global investments.
·The company reported a 13% revenue increase for FY26, but net profit declined.
·Biocon is exploring in-licensing for its biosimilars and focusing on profitable growth.